2017 FDA Peptide Harvest

Othman Al Musaimi; Danah Al Shaer; Beatriz G de la Torre; Fernando Albericio

doi:10.3390/ph11020042

2017 FDA Peptide Harvest

Pharmaceuticals (Basel). 2018 May 7;11(2):42. doi: 10.3390/ph11020042.

Authors

Othman Al Musaimi^{1

2}, Danah Al Shaer^{3

4}, Beatriz G de la Torre⁵, Fernando Albericio^{6

7

8}

Affiliations

¹ College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa. musamiau@gmail.com.
² School of Chemistry, University of KwaZulu-Natal, Durban 4001, South Africa. musamiau@gmail.com.
³ College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa. danah.shaer@gmail.com.
⁴ School of Chemistry, University of KwaZulu-Natal, Durban 4001, South Africa. danah.shaer@gmail.com.
⁵ KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. garciadelatorreb@ukzn.ac.za.
⁶ School of Chemistry, University of KwaZulu-Natal, Durban 4001, South Africa. albericio@ukzn.ac.za.
⁷ CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, University of Barcelona, 08028 Barcelona, Spain. albericio@ukzn.ac.za.
⁸ Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain. albericio@ukzn.ac.za.

Abstract

2017 was an excellent year in terms of new drugs (chemical entities and biologics) approved by the FDA, with a total of 46. In turn, one of the highlights was the number of peptides (six) included in this list. Here, the six peptides are analyzed in terms of chemical structure, synthetic strategy used for their production, source, therapeutic use, and mode of action.

Keywords: drug discovery; drugs; pharmaceutical market; solid-phase peptide synthesis.

Publication types

Review